within Pharmacolibrary.Drugs.ATC.M;

model M01AB08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0008166666666666667,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0104,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0085,
    Tlag           = 0,            
    Vdp             = 0.006,
    k12             = 8.3,
    k21             = 8.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AB08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) used for the management of mild to moderate pain, osteoarthritis, and rheumatoid arthritis. It is commonly administered orally and is approved for medical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single 200 mg oral dose.</p><h4>References</h4><ol><li><p>Davis, JL, et al., &amp; Campbell, NB (2007). Pharmacokinetics of etodolac in the horse following oral and intravenous administration. <i>Journal of veterinary pharmacology and therapeutics</i> 30(1) 43–48. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.2007.00811.x\">10.1111/j.1365-2885.2007.00811.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17217400/\">https://pubmed.ncbi.nlm.nih.gov/17217400</a></p></li><li><p>Benet, LZ (1993). Pharmacokinetics of sustained-release etodolac. <i>Rheumatology international</i> 13(2 Suppl) S3–S5. DOI:<a href=\"https://doi.org/10.1007/BF00290277\">10.1007/BF00290277</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8210922/\">https://pubmed.ncbi.nlm.nih.gov/8210922</a></p></li><li><p>Baek, IH (2019). Pharmacokinetic modeling and simulation of etodolac following single oral administration in dogs. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(8) 981–986. DOI:<a href=\"https://doi.org/10.1080/00498254.2018.1524185\">10.1080/00498254.2018.1524185</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30216103/\">https://pubmed.ncbi.nlm.nih.gov/30216103</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AB08;
